Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
—
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
—
Daily adjusted close
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.